Skip to main content

Advertisement

SpringerLink
Log in

Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to identify the biomarkers associated with chemotherapeutic efficacy and long-term survival for patients with advanced squamous cell carcinoma of the esophagus (SCCE) who had received neoadjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil (NAC-DCF).

Methods

This study included 45 patients with advanced SCCE who received NAC-DCF between 2008 and 2012. The NAC-DCF was conducted as a phase II study (UMIN000007408). The expressions of excision repair cross-complementing-1 (ERCC1), class III beta-tubulin, breast cancer susceptibility gene I (BRCA1), and thymidylate synthase were investigated simultaneously in the pre-treatment endoscopic tumor biopsy samples.

Results

A multivariate logistic regression analysis indicated that pathological responses were significantly associated with tumors with low ERCC1 expression (P = 0.016) and with tumors with high BRCA1 expression (P = 0.030). The multivariate Cox proportional hazard model analysis for relapse-free survival revealed high BRCA1 expression (P = 0.031, hazards ratio 4.39) as the factor associated with survival.

Conclusions

Low ERCC1 expression and high BRCA1 expression in patients with SCCE were associative biomarkers for chemotherapeutic efficacy. High BRCA1 expression was considered the factor associated with survival. These findings may be helpful for tailoring chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with CDDP and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74. doi:10.1245/s10434-011-2049-9.

    Article  PubMed  Google Scholar 

  2. Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M, et al. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Ann Surg Oncol. 2014;21:2838–44. doi:10.1245/s10434-014-3684-8.

    Article  PubMed  Google Scholar 

  3. Ui T, Fujii H, Hosoya Y, Nagase M, Mieno MN, Mori M, et al. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus. Dis Esophagus. 2015;28:180–7. doi:10.1111/dote.12187.

    Article  CAS  PubMed  Google Scholar 

  4. Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104:1455–60. doi:10.1111/cas.12274.

    Article  CAS  PubMed  Google Scholar 

  5. Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, et al. Neoadjuvant chemotherapy with divided-dose docetaxel, cisplatin and fluorouracil for patients with squamous cell carcinoma of the esophagus. Anticancer Res. 2016;36:829–34.

    CAS  PubMed  Google Scholar 

  6. Holm B, Mellemgaard A, Skov T, Skov BG. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27:4254–9. doi:10.1200/JCO.2008.18.8631.

    Article  CAS  PubMed  Google Scholar 

  7. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005;11:2215–21.

    Article  PubMed  Google Scholar 

  8. Warnecke-Eberz U, Vallböhmer D, Alakus H, Kütting F, Lurje G, Bollschweiler E, et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg. 2009;13:1411–21. doi:10.1007/s11605-009-0881-z.

    Article  PubMed  Google Scholar 

  9. Langer R, Specht K, Becker K, Ewald P, Bekesch M, Sarbia M, et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res. 2005;11:7462–9.

    Article  CAS  PubMed  Google Scholar 

  10. Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, et al. High specificity of quantitative excision repair cross-complementing-1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res. 2004;10:3794–9.

    Article  CAS  PubMed  Google Scholar 

  11. Tanaka K, Mohri Y, Ohi M, Yokoe T, Koike Y, Morimoto Y, et al. Excision-repair cross-complementing-1 predicts response to cisplatin-based neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. Mol Med Rep. 2009;2:903–9. doi:10.3892/mmr_00000190.

    Article  CAS  PubMed  Google Scholar 

  12. Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, et al. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer. 2013;14:558–67. doi:10.1016/j.cllc.2013.04.013.

    Article  CAS  PubMed  Google Scholar 

  13. Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C. Class III β-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med. 2011;11:726–31.

    Article  CAS  PubMed  Google Scholar 

  14. Weberpals JI, Tu D, Squire JA, Amin MS, Islam S, Pelletier LB, et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol. 2011;22:2403–10. doi:10.1093/annonc/mdq770.

    Article  CAS  PubMed  Google Scholar 

  15. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375–9. doi:10.1200/JCO.2008.20.7019.

    Article  CAS  PubMed  Google Scholar 

  16. Weberpals J, Garbuio K, O’Brien A, Clark-Knowles K, Doucette S, Antoniouk O, et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer. 2009;124:806–15. doi:10.1002/ijc.23987.

    Article  CAS  PubMed  Google Scholar 

  17. Gao Y, Zhu J, Zhang X, Wu Q, Jiang S, Liu Y, et al. BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. PLoS One. 2013;8:e52589. doi:10.1371/journal.pone.0052589.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Harpole DH Jr, Moore MB, Herndon JE 2nd, Aloia T, D’Amico TA, Sporn T, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001;7:562–9.

    PubMed  Google Scholar 

  19. Yu Y, Ding S, Liang Y, Zheng Y, Li W, Yang L, et al. Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: a hierarchical clustering analysis. Exp Ther Med. 2014;7:1578–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Sobin LH, Wittekind CH. International Union Against Cancer (UICC): TNM classification of malignant tumors. UICC Cancer Staging Manual. 6th ed. New York: Wiley; 2002.

    Google Scholar 

  21. Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Matsumura S, et al. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil (DCF) for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. Dis Esophagus. 2016;. doi:10.1111/dote.12450 (epub ahead of print).

    PubMed  Google Scholar 

  22. Ojima T, Iwahashi M, Nakamori M, Nakamura M, Katsuda M, Iida T, et al. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg Today. 2014;44:839–47. doi:10.1007/s00595-013-0616-3.

    Article  PubMed  Google Scholar 

  23. Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: part I. Esophagus. 2009;6:1–25.

    Article  Google Scholar 

  24. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.

    Article  CAS  PubMed  Google Scholar 

  25. Handra-Luca A, Bilal H, Bertrand JC, Fouret P. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol. 2003;163:957–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol. 1999;155:2057–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol. 2014;74:777–86. doi:10.1007/s00280-014-2562-1.

    Article  CAS  PubMed  Google Scholar 

  28. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994;54:3500–5.

    CAS  PubMed  Google Scholar 

  29. Sun JM, Ahn MJ, Park MJ, Lee HY, Ahn JS, Lee S, et al. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;80:655–60. doi:10.1016/j.ijrobp.2010.02.061.

    Article  PubMed  Google Scholar 

  30. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44:54–60.

    Article  CAS  PubMed  Google Scholar 

  31. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18:504–9.

    Article  PubMed  Google Scholar 

  32. Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet. 2002;360:1007–14.

    Article  CAS  PubMed  Google Scholar 

  33. Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst. 2011;103:1552–6. doi:10.1093/jnci/djr326.

    Article  CAS  PubMed  Google Scholar 

  34. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999;97:575–86.

    Article  CAS  PubMed  Google Scholar 

  35. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene. 2001;20:6597–606.

    Article  CAS  PubMed  Google Scholar 

  36. Saeki H, Nakashima Y, Zaitsu Y, Tsuda Y, Kasagi Y, Ando K, et al. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today. 2016;46:261–7. doi:10.1007/s00595-015-1144-0.

    Article  CAS  PubMed  Google Scholar 

  37. Kosumi K, Baba Y, Ishimoto T, Harada K, Nakamura K, Ohuchi M, et al. Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients. Surg Today. 2016;46:405–13. doi:10.1007/s00595-015-1197-0.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Department of Surgery, School of Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8510, Japan

    Toshiyasu Ojima, Mikihito Nakamori, Masaki Nakamura, Masahiro Katsuda, Keiji Hayata & Hiroki Yamaue

  2. Department of Clinical Laboratory Medicine, Wakayama Medical University, Wakayama, Japan

    Yasushi Nakamura

Authors
  1. Toshiyasu Ojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mikihito Nakamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaki Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiro Katsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keiji Hayata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasushi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroki Yamaue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroki Yamaue.

Ethics declarations

Conflict of interest

Drs. Ojima, Nakamori, Nakamura M, Katsuda, Hayata, Nakamura Y and Yamaue declare no conflicts of interest or financial ties in association with the present study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ojima, T., Nakamori, M., Nakamura, M. et al. Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. Surg Today 47, 65–73 (2017). https://doi.org/10.1007/s00595-016-1338-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-016-1338-0

Keywords

Search

Navigation